Titan Pharmaceuticals Announces $9.5 Million Private Placement of Convertible Preferred Stock September 18, 2023
UPDATE -- Titan Pharmaceuticals Inc. Announces Licensing Agreement with Ocular Therapeutix Inc. December 12, 2022
Titan Pharmaceuticals Announces Pricing of $5.5 Million Registered Direct and PIPE Offering Priced At-The-Market February 2, 2022
Sustained Anti-Pruritic Effect Of Titan's TP-2021 Implant Reported Today At Neuroscience 2021 November 8, 2021
